Skip to main content
HANALL BIOPHARMA CO.,LTD logo

HANALL BIOPHARMA CO.,LTD — Investor Relations & Filings

Ticker · 009420 ISIN · KR7009420001 KO Manufacturing
Open in API
Filings indexed 335 across all filing types
Latest filing 2026-05-28 Investor Presentation
Country KR South Korea
Listing KO 009420

About HANALL BIOPHARMA CO.,LTD

http://www.hanallbiopharma.com/

HanAll Biopharma is a global biopharmaceutical company focused on developing innovative, first-in-class therapies for patients with unmet medical needs. The company's research and development efforts are centered on immunology, ophthalmology, and immuno-oncology, with a specialization in antibody-based therapeutics. Its pipeline includes novel treatments for autoimmune diseases and dry eye disease. The company's mission is to pioneer cutting-edge medicines that address incurable and immune-associated conditions. Alongside its innovative pipeline, HanAll Biopharma also operates a portfolio of pharmaceutical products in therapeutic areas including endocrine, circulatory, and urologic diseases.

Recent filings

Filing Released Lang Actions
기업설명회(IR)개최(안내공시)
Investor Presentation Classification · 92% confidence The document is a public announcement in Korean for an upcoming 기업설명회 (Investor Relations presentation/Non-Deal Roadshow) on 2026-05-29, detailing date, venue, participants, purpose, method, and IR materials. This is an event notice for an investor presentation, matching the definition of category IP (Investor Presentation).
2026-05-28 Korean
[기재정정]투자판단관련주요경영사항
Regulatory Filings Classification · 85% confidence The document is a Korean correction notice (“정정신고(보고)”) to a prior “투자판단 관련 주요경영사항” announcement, outlining amendments to a previously filed investment decision related management disclosure. It does not contain actual financial statements, earnings data, or detailed report content itself, nor is it a presentation or transcript. It simply corrects a prior regulatory filing, falling into the miscellaneous regulatory announcement category. Therefore, it should be classified as a general Regulatory Filing (RNS).
2026-05-20 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 88% confidence The document is a detailed quarterly report (“분기보고서”) covering the first quarter of fiscal 2026, including full business overview, financial tables, operational data, and risk management. It is the actual report itself (not just an announcement) and contains substantive financial statements and analysis for a period shorter than a full year. Therefore, it should be classified as an Interim / Quarterly Report. Q1 2026
2026-05-15 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' which translates to 'Report on Ownership of Specific Securities by Executives and Major Shareholders.' It contains detailed information about the securities owned by an individual named 안혜경, including the number of shares, ownership percentages, and changes in holdings. The document is addressed to regulatory bodies such as the Securities and Futures Commission and the Korea Exchange, indicating it is a formal disclosure of insider holdings. This matches the definition of a 'Director's Dealing' report, which involves reporting personal share transactions by company directors and executives. The document is not an announcement of a report, nor does it contain financial statements or management commentary, so it does not fit other categories like Annual Report or Earnings Release. Therefore, the correct classification is DIRS (Director's Dealing).
2026-05-06 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' which translates to 'Report on Ownership Status of Specific Securities by Executives and Major Shareholders.' It includes detailed information about securities ownership changes by an executive named 정승원, including dates, types of securities, quantities, and ownership percentages. The document is addressed to regulatory bodies such as the Securities and Futures Commission and the Korea Exchange. This type of filing corresponds to notifications about insider or director shareholdings and transactions. Given the content and purpose, this matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives. The document length is short and focused on ownership changes, not a full financial report or announcement. Therefore, the correct classification is DIRS with high confidence.
2026-05-06 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' which translates to 'Report on Ownership Status of Specific Securities by Executives and Major Shareholders.' It contains detailed information about the ownership of securities by an executive named 박승국, including the number of shares owned, changes in ownership, and related dates. The document is addressed to regulatory bodies such as the Securities and Futures Commission and the Korea Exchange. This type of filing corresponds to a notification of changes in significant share ownership levels, which matches the definition of 'Major Shareholding Notification' (Code: MRQ). The document length is 2487 characters, which is consistent with a detailed ownership report rather than a brief announcement or a full financial report. Therefore, the correct classification is MRQ with high confidence.
2026-05-06 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.